In this review I attempt to advance hypotheses that might help contribute toward understanding the molecular pathogenesis of cerebral malaria (CM) and other complications based on a now widely accepted argument that the illness and pathology occasioned by Plasmodiumfalciparum infection might not necessarily be due to the direct effects of the parasite’s ‘toxins’ and/or exoantigens or even its sequestration and consequent attendant effects in vital organs but rather to the parasite’s mediated production of microbicidal molecules by the host. Tumor necrosis factor (TNF)-α is implicated in the pathogenesis of complicated malaria. There is a positive correlation between high levels of TNF-α and severity of malaria. The role of nitric oxide in the pathophysiology of complicated malaria is not clearly understood. Mononuclear phagocytes by virtue of their capacity to secrete toxic intermediates like reactive oxygen intermediates can inhibit the growth of both murine and human plasmodia. The role of interleukin-10 (IL-10) in malaria is also not well characterized to date. IL-10 is a powerful immunosuppressor factor. It acts as a natural dampener of immunoproliferative and inflammatory responses. Although transforming growth factor-β has a crucial role in inflammation and repair, its role in complicated malaria is not too clearly understood. Furthermore, the anatomical source of these microbicidal molecules is not precisely known. The role of immune complexes (IC) in the pathophysiology of complicated malaria has hitherto not been tested. I argue here that IC play a critical role in influencing the outcome of malarial disease; IC-mediated stimulation of leukocytes to produce high levels of both TNF-α and NO and the fact that leukocytes are probably the principal anatomical source of these microbicidal and other pro-inflammatory mediators in complicated malaria provide a much more plausible explanation for the pathogenesis of CM and other complications. I also review the arguments that help contribute to rationalize hypoglycemia and hyperlactatemia in malarial disease and to some extent severe anemia. I am therefore tempted to conclude that CM and other complications are probably immune-mediated diseases or, at least, they present an inflammatory pathogenesis.

Keywords:
Cerebral malaria, Immune complexes, Interleukin-10, Leukocytes, Nitric oxide, Plasmodium falciparum, Reactive oxygen intermediates, Recruitment, Sequestration, Transforming growth factor-β
1.
World Health Organization (WHO): African Malaria Report, 2003.
2.
Stanley J: Malaria. Emerg Med Clin North Am 1997;15:113–155.
3.
Robbins R, Cotran S, Tucker VK, Stanley C, Robbins L, Schmitt B: Pathologic Basis of Disease, ed 6. New York, Saunders, 1999.
4.
Cottrell BJ: Cell-mediated immunity in mice vaccinated against malaria. Clin Exp Immunol 1978;34:147.
5.
Clark IA: Does endotoxin cause both the disease and parasite death in acute malaria and babesiosis? Lancet 1978;ii:75–77.
6.
Clark IA, Virelizier JL, Carswell EA, Wood PR: Possible importance of macrophage-derived mediators in malaria. Infect Immun 1981;32:1058–1066.
7.
Clark IA: Suggested importance of monokines in pathophysiology of endotoxin shock and malaria. Klin Wochenschr 1982;60:756–758.
8.
Clark IA: Cell-mediated immunity in protection and pathology of malaria. Parasitol Today 1987;3:300–305.
9.
Spriggs DR, Sherman ML, Michie H, Arthur KA, Imura K, Wilmore D, Frei E, Kufe DW: Recombinant tumor necrosis factor administered as a 24-hour intravenous infusion. A phase 1 and pharmacologic study. J Natl Cancer Inst 1988;80:1039–1044.
10.
Butcher GA, Garland T, Adjuckiewicz AB, Clark IA: Serum tumor necrosis factor associated with malaria in patients in the Solomon Islands. Trans R Soc Trop Med Hyg 1990;85:658–661.
11.
Grau GE, Piquet PF, Vassalli P, Lambert PH: Tumor necrosis factor and other cytokines in cerebral malaria. Experimental and clinical data. Immunol Rev 1989;112:49–70.
12.
Kern P, Hemmer CJ, Van Damme J, Gruss HJ, Dietrich M: Elevated tumor necrosis factor alpha and interleukin-6 serum levels as markers for complicated Plasmodium falciparum malaria. Am J Med 1989;87:139–143.
13.
Kwiatkowski D, Hill AV, Sambou I, Twumasi P, Castracane K, Monogue R, Cerami AD, Greenwood BM: TNF concentration in fatal cerebral, non-fatal cerebral, and uncomplicated P. falciparum malaria. Lancet 1990;336:1201–1204.
14.
Bate CA, Taverne J, Playfair JH: Malarial parasites induce TNF production by macrophages. Immunology 1988;64:227–231.
15.
Schofield L, Hackett F: Signal transduction in host cells by a glycosylphosphatidylinositol toxin of malaria parasites. J Exp Med 1993;177:145–153.
16.
Carswell EA, Old LJS, Kassel RL, Green S, Fiore N, Williamson B: An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 1975;72:3666–3670.
17.
Manel DN, Moore RN, Mergenhagen SE: Macrophages as a source of tumoricidal activity (tumor-necrotizing factor). Infect Immun 1980;30:523–530.
18.
Degliantoni G, Murphy M, Kobayashi M, Francis MK, Perussia B, Trinchieri G: Natural killer (NK) cell-derived hematopoietic colony-inhibiting activity and NK cytotoxic factor. Relationship with tumor necrosis factor and synergism with immune interferon. J Exp Med 1985;162:1512–1530.
19.
Paya CV, Kenmotsu N, Schoon RA, Leibson PJ: Tumor necrosis factor and lymphotoxin secretion by human natural killer cells leads to antiviral cytotoxicity. J Immunol 1988;141:1989–1995.
20.
Richards AL, Dennert G, Pluznik DH, Takagaki Y, Djeu JY: Natural cytotoxic activity in a cloned natural killer cell line is mediated by tumor necrosis factor. Nat Immun Cell Growth Regul 1989;8:76–88.
21.
Costa JJ, Matossian K, Resnick MB, Beil WJ, Wong DTW, Gordon JR, Dvorak AM, Weller PF, Galli SJ: Human eosinophils can express the cytokines tumor necrosis factor-alpha and macrophage inflammatory protein-1 alpha. J Clin Invest 1993,91:2673–2684.
22.
Kobayashi M, Fitz L, Ryan M, Hewick RM, Clark SC, Chan S, Loudon R, Sherman F, Perussia B, Trinchieri G: Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biological effects on human lymphocytes. J Exp Med 1989;170:827–845.
23.
Haranaka K, Sateomi N, Sakurai A: Antitumor activity of murine tumor necrosis factor against transplanted murine tumors and heterotransplanted human tumors in nude mice. Int J Cancer 1984;34:263–267.
24.
Feinman R, Heriken-DeStafano D, Tsujimoto M: TNF is an important mediator of tumor cell killing by human monocytes. J Immunol 1987;138:635–640.
25.
Tomazic VJ, Farha M, Loftus A, Elias EG: Anti-tumor activity of recombinant tumor necrosis factor on mouse fibrosarcoma in vivo and in vitro. J Immunol 1988;140:4056–4061.
26.
Mestan J, Digel W, Mittnacht S, Hillen H, Blohm D, Moller A, Jacobsin H, Miller LH, Good MF, Milon G: Malaria pathogenesis. Science 1994;264:1878–1883.
27.
Silberstein DS, David JR: Tumor necrosis factor enhances eosinophil toxicity to Schistosoma mansoni larvae. Proc Natl Acad Sci USA 1986;83:1055.
28.
Esparza I, Mannel D, Ruppel A, Falk W, Krammer PH: Interferon gamma and lymphotoxin or tumor necrosis factor act synergistically to induce macrophage killing of tumor cells and schistosomula of Schistosoma mansoni. J Exp Med 1987;166:589–594.
29.
Liew F, Li Y, Millot S: Tumor necrosis factor-α synergizes with IFN-γ in mediating killing of Leishmania major through the induction of nitric oxide. J Immunol 1990;145:4306–4310.
30.
Djeu JY, Blanchard DK, Halkias D, Friedman H: Growth inhibition of Candida albicans by human polymorphonuclear neutrophils: Activation by interferon-gamma and tumor necrosis factor. J Immunol 1986;137:2980–2984.
31.
Dinarello CA, Cannon JG, Wolff SM, Bernheim HA, Beutler B, Cerami A, Figari IS, Palladino MA, O’Connor JV: Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin-1. J Exp Med 1986;163:1433–1450.
32.
Kwiatkowski D, Molyneux ME, Stephens S, Curtis N, Klein N, Pointaire P, Smit M, Allan R, Brewster DR, Grau GE, Greenwood BM: Anti-TNF therapy inhibits fever in cerebral malaria. Q J Med 1993;86:91–98.
33.
Grau GE, Taylor TE, Molyneux ME, Wirima JJ, Vassalli P, Hommel M, Lambert PH: Tumor necrosis factor and disease severity in children with falciparum malaria. N Engl J Med 1989;320:1586–1591.
34.
Grau GE, Fajardo LF, Piguet PF, Allet B, Lambert PH, Vassali P: Tumor necrosis factor (cachectin) as an essential mediator in murine cerebral malaria.. Science 1987;237:1210–1212.
35.
Knowles RG, Moncada S: Nitric oxide synthase in mammals. Biochem J 1994;298:249–258.
36.
Morris SM Jr, Billiar TR: New insights into the regulation of inducible nitric oxide synthesis. Am J Physiol 1994;266:E829–E839.
37.
Nathan CF, Hibbs JB Jr: Role of nitric oxide synthesis in macrophage antimicrobial activity (review). Curr Opin Immunol 1991;3:65–70.
38.
Sessa WC: The nitric oxide synthase family of proteins. J Vasc Res 1994;31:131–143.
39.
Stuehr DJ, Griffith OW: Mammalian nitric oxide synthases. Adv Enzymol Relat Areas Mol Biol 1992;65:287–346.
40.
Moncada S, Palmer RM, Higgs EA: Biosynthesis of nitric oxide from L-arginine: A pathway for the regulation of cell function and communication. Biochem Pharmacol 1989;38:1709–1715.
41.
Moncada S, Higgs EA: The L-arginine-nitric oxide pathway. N Engl J Med 1993;329:2002–2012.
42.
Garthwaite J: Glutamate, nitric oxide and cell-cell signaling in the nervous system. Trends Neurosci 1991;14:60–67.
43.
Snyder SH, Bredt DS: Biological roles of nitric oxide. Sci Am 1992;266:68–71.
44.
Murad F, Ishii K, Forstermann U, Gorsky L, Kerwin JF Jr, Pollock J, Heller M: EDRF is an intracellular second messenger and autacoid to regulate cyclic GMP synthesis in many cells. Adv Second Messenger Phosphoprotein Res 1990;24:441–448.
45.
Ignarro LJ: Heme-dependent activation of guanylate cyclase by nitric oxide: A novel signal transduction mechanism. Blood Vessels 1991;28:67–73.
46.
Nussler AK, Eling W, Kremsher PG: Patients with Plasmodium falciparum malaria and Plasmodiumvivax malaria show increased nitrite and nitrate plasma levels. J Infect Dis 1994;169:1418–1419.
47.
Hibbs JB Jr, Taintor RR, Vavrin Z, Rachlin EM: Nitric oxide: A cytotoxic activated macrophage effector molecule. Biochem Biophys Res Commun 1988;157:87–94.
48.
Marletta MA, Yoon PS, Iyengar R, Leaf CD, Wishnok JS: Macrophage oxidation of L-arginine to nitrite and nitrate: Nitric oxide is an intermediate. Biochemistry 1988;27:8706–8711.
49.
Stuehr DJ, Gross SS, Sakuma I, Levi R, Nathan CF: Activated murine macrophages secrete a metabolite of arginine with the bioactivity of endothelium-derived relaxing factor and the chemical reactivity of nitric oxide. J Exp Med 1989;169:1011–1020.
50.
Hibbs JB Jr, Taintor RR, Vavrin Z, Granger DL, Drapier JC, Amber IJ, Lancaster JR Jr: Synthesis of nitric oxide from a terminal guanidino nitrogen atom of L-arginine: A molecular mechanism regulating cellular proliferation that targets intracellular iron; in Moncada S, Higgs EA (eds): Nitric Oxide from L-Arginine: A Bioregulatory System. Amsterdam, Elsevier, 1990, pp 189–223.
51.
Nguyen T, Brunson D, Crespi CL, Penman BW, Wishnok JS, Tannenbaum SR: DNA damage and mutation in human cells exposed to nitric oxide in vitro. Proc Natl Acad Sci USA 1992;89:3030–3034.
52.
Madaio MP: The role of autoantibodies in the pathogenesis of lupus nephritis. Semin Nephrol 1999;19:48–56.
53.
Korganow AS, Ji H, Mangialaio S, Duchatelle V, Pelanda R, Martin T, Degott C, Kikutani H, Rajewsky K, Pasquali JL, Benoist C, Mathis D: From systemic T cell self-reactivity to organ-specific autoimmune disease via immunoglobulins. Immunity 1999;10:451–461.
54.
Bolton WK: Goodpasture’s syndrome (review). Kidney Int 1996;50:1753–1766.
55.
Ando M, Suga M: Hypersensitivity pneumonitis. Curr Opin Pulm Med 1997;3:391–395.
56.
Dugas B, Mossalayi MD, Damais C, Kolb JP: Nitric oxide production by human monocytes: Evidence for a role of CD23. Immunol Today 1995;16:574–580.
57.
Voldoukis I, Issaly F, Fourcade C, Paul-Eugene N, Arock M, Kolb JP, da Silva AO, Monjour L, Poinsot H, Tselentis Y, Dugas B, Debre P, Mossalayi MD: CD23 and IgE expression during the human immune response to cutaneous leishmaniasis: possible role in monocyte activation. Res Immunol 1994;145:17–27.
58.
Perlmann P, Perlmann H, Flyg BW, Hagstedt M, Elghazali G, Worku S, Fernandez V, Rutta AM, Troye-Blomberg M: Immunoglobulin E, a pathogenic factor in Plasmodium falciparum malaria. Infect Immun 1997;65:116–121.
59.
Perlmann P, Perlmann H, ElGhazali G, Troye-Blomberg M: IgE and tumor necrosis factor in malaria infection (review). Immunol Lett 1999;65:29–33.
60.
Perlmann H, Helmby H, Hagstedt M, Carlson J, Larsson PH, Troye-Blomberg M, Perlmann P: IgE elevation and IgE anti-malarial antibodies in Plasmodium falciparum malaria: Association of high IgE levels with cerebral malaria. Clin Exp Immunol 1994;97:284–292.
61.
Clark IA, Hunt NH: Evidence for reactive oxygen intermediates causing hemolysis and parasite death in malaria. Infect Immun 1983;39:1–6.
62.
Ockenhouse CF, Schulman S, Shear HL: Induction of crisis forms in the human malaria parasite Plasmodium falciparum by gamma-interferon-activated, monocyte-derived macrophages. J Immunol 1984;133:1601–1608.
63.
Wozencraft AO, Dockrell HM, Taverne J, Targett GA, Playfair JH: Killing of human malaria parasites by macrophage secretory products. Infect Immun 1984;43:664–669.
64.
Lunel F, Druilhe P: Effector cells involved in nonspecific and antibody-dependent mechanisms directed against Plasmodium falciparum blood stages in vitro. Infect Immun 1989;57:2043–2049.
65.
Jones KR, Cottrell BJ, Targett GA, Playfair JHL: Killing of Plasmodium falciparum by human monocyte-derived macrophages. Parasite Immunol 1989;11:585–592
66.
Trager W, Jensen JB: Human malaria parasites in continuous culture. Science 1976;193:673–675.
67.
Allison AC, Eugui EM: The role of cell-mediated immune responses in resistance to malaria, with special reference to oxidant stress. Annu Rev Immunol 1983;1:361–392.
68.
Moore KW, de Waal Malefyt R, Coffman RL, O’Garra A: Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001;19:683–765.
69.
Brown H, Turner G, Rogerson S, Tembo M, Mwenechanya J, Molyneux M, Taylor T: Cytokine expression in the brain in human cerebral malaria. J Infect Dis 1999;180:1742–1764.
70.
Kwiatkowski D, Cannon JG, Manogue KR, Cerami A, Dinarello C A, Greenwood B: Tumour necrosis factor production in falciparum malaria and its association with schizont rupture. Clin Exp Immunol 1989;77:361–366.
71.
De Kossodo S, Grau GE: Role of cytokines and adhesion molecules in malaria immunopathology. Stem Cells 1993;11:41–48.
72.
Sporn MB, Roberts AB, Wakefield LM, Crombugghe B: Some recent advances in the chemistry and biology of transforming growth factor-β. J Cell Biol 1987;105:1039–1045.
73.
Oo MM, Aikawa M, Than T, Aye TM, Myint PT, Igarshi I, Schoene WC: Human cerebral malaria: A pathological study. J Neuropathol Exp Neurol 1987;46:223–231.
74.
World Health Organization (WHO). Trends in health. World Health Stat Q 1995;48:192.
75.
Aikawa M, Iseki M, Barnwell JW, Taylor D, Oo MM, Howard R: The pathology of human cerebral malaria. Am J Trop Med Hyg 1990;43:30–37.
76.
Miller LH, Good MF, Milon G: Malaria pathogenesis. Science 1994;264:1878–1883.
77.
Azizul H, Echchannaoui H, Seguin R, Schwartzman J, Kasper HL, Haque S: Cerebral malaria in mice: IL-2 treatment induces accumulation of γδ T cells in the brain and alters resistant mice to susceptible-like phenotype. Am J Pathol 2001;158:163–172.
78.
Mota M, Jarra W, Hirst E, Patnaik PK, Hol der AA: Plasmodium chabaudi-infected erythrocytes adhere to CD36 and bind to microvascular endothelial cells in an organ-specific way. Infect Immun 2000;4135–4144.
79.
Berendt AR, Simmons DL, Tansey J, Newbold CI, Marsh K: Intercellular adhesion molecule-1 is an endothelial cell adhesion receptor for Plasmodium falciparum. Nature 1989;341:57–59.
80.
Schofield L, Novakovic S, Gerold P, Schwarz RT, McConville MJ, Tachado SD: Glycosylphosphatidylinositol toxin of Plasmodium up-regulates intercellular adhesion molecule-1, vascular cell adhesion molecule-1, and E-selectin expression in vascular endothelial cells and increases leukocyte and parasite cytoadherence via tyrosine kinase-dependent signal transduction. J Immunol 1996;156:1897–1907.
81.
Bondi FS: The incidence and outcome of neurological abnormalities in childhood cerebral malaria: A long term follow-up of 62 survivors. Trans R Soc Trop Med Hyg 1992;86:17–19.
82.
Brewster DR, Kwiatkowski D, White NJ: Neurological sequelae of cerebral malaria in children. Lancet 1990;336:1039–1043.
83.
Holding PA, Stevenson J, Peshu N: Cognitive sequelae of severe malaria with impaired consciousness. Trans R Soc Trop Med Hyg 1999;93:529–534.
84.
Clark IA, Rockett KA, Cowden WB: Possible central role of nitric oxide in conditions clinically similar to cerebral malaria. Lancet 1992;894–896.
85.
Al Yaman FM, Mokela D, Genton B, Rockett KA, Alpers MP, Clark IA: Association between serum levels of reactive nitrogen intermediates and coma in children with cerebral malaria in Papua New Guinea. Trans R Soc Trop Med Hyg 1996;90:270–273.
86.
Anstey NM, Weinberg JB, Hassanali MY, Mwaikambo ED, Manyenga D, Misukonis MA, Arenelle DR, Hollis D, McDonald MI, Granger DL: Nitric oxide in Tanzanian children with malaria: inverse relationship between malaria severity and nitric oxide production/nitric oxide synthase type 2 expression. J Exp Med 1996;184:557–567.
87.
Bohme GA, Bon C, Lemaire M, Reibaud M, Piot O, Statzmann JM, Doble A, Blanchard JL: Altered synaptic plasticity and memory formation in nitric oxide synthase inhibitor-treated rats. Proc Natl Acad Sci USA 1993;90:9191–9194.
88.
Daniel H, Hemart N, Jaillard D, Crepel F: Long-term depression requires nitric oxide and guanosine 3′:5′ cyclic monophosphate production in rat cerebellar Purkinje cells. Eur J Neurosci 1993;5:1079–1082.
89.
Montague PR, Gancayco CD, Winn MJ, Marchase RB, Friedlander MS: Role of NO production in NMDA receptor-mediated neurotransmitter release in cerebral cortex. Science 1994;163:973–977.
90.
Rockett KA, Kwiatkowski D, Bate CA, Awburn MM, Rockett EJ, Clark IA: In vitro induction of nitric oxide by an extract of Plasmodium falciparum. J Infect 1996;32:187–196.
91.
Tachado SD, Gerold P, Schwarz R, Novakovic S, McConville M, Schofield L: Signal transduction in macrophages by glycosylphosphatidylinositols of Plasmodium, Trypanosoma, and Leishmania: Activation of protein tyrosine kinases and protein kinase C by inositolglycan and diacylglycerol. Proc Natl Acad Sci USA 1996;94:4022–4027.
92.
Manzoni OL, Prezeau P, Marin P, Desharger S, Bockaert J, Fagni L: Nitric oxide-induced blockade of NMDA receptors. Neuron 1992;8:653–662.
93.
Lei SZ, Pan ZH, Aggarwal SK, Chen HS, Hartman VJ, Sucher NJ, Lipton SA: Effect of nitric oxide production on the redox modulatory site of the NMDA receptor-channel complex. Neuron 1992;8:1087–1099.
94.
Lovinger DM, White G, Weight FF: Ethanol inhibits NMDA-activated ion current in hippocampal neurons. Science 1989;243:1721–1724.
95.
Puil E, El-Beheiry H, Baimbridge KG: Anaesthetic effects on glutamate-stimulated increase in intraneuronal calcium. J Pharmacol Exp Ther 1990;255:955–961.
96.
Bianchi M, Battistin T, Galzigna L: 2,6-Diisopropylphenol, a general anesthetic, inhibits glutamate action on rat synaptosomes. Neurochem Res 1991;16:443–446.
97.
Carla V, Moroni F: General anaesthestics inhibit the responses induced by glutamate receptor agonists in the mouse cortex. Neurosci Lett 1992;146:21–24.
98.
Aronstam RS, Martin D, Dennison RL: Volatile anesthetics inhibit NMDA-stimulated 45Ca uptake by rat brain microvesicles. Neurochem Res 1994;19:1515–1520.
99.
Anonymous: Memorandum 24 on Medical Diseases in Tropical and Sub-Tropical Areas. London, War Office, 1942.
100.
Clark IA, Rockett KA, Cowden WB: Proposed link between cytokines, nitric oxide and human cerebral malaria. Parasitol Today 1991;7:205–207.
101.
Chouchakova N, Skokowa J, Baumann U, Tscherning T, Phillippens KMH, Nieswandt B, Schmidt RE, Gessner JE: FcγRIII-mediated production of TNF-α induces immune complex alveolitis independently of CXC chemokine generation. J Immunol 2001;166:5193–5200.
102.
Maeno Y, Perlmann P, Perlmann H, Kusuhara Y, Taniguchi K, Nakabayashi T, Win K, Looareesuwan S, Aikawa M: IgE deposition in brain microvessels and on parasitized erythrocytes from cerebral malaria patients. Am J Trop Med Hyg 2000;63:128–132.
103.
Borish L, Mascali JJ, Rosenwasser LJ: IgE-dependent cytokine production by human peripheral blood mononuclear phagocytes. J Immunol 1991;146:63–67.
104.
Jakobsen PH, Bate CA, Taverne J, Playfair JH: Malaria: Toxins, cytokines and disease. Parasite Immunol 1995;17:223–231.
105.
Kwiatkowski D: Malarial toxins and the regulation of parasite density. Parasitol Today 1995;11:206–212.
106.
McConville MJ, Ferguson MAJ: The structure, biosynthesis, and function of glycosylated phosphatidylinositols in the parasite protozoa, higher eukaryotes (review). Biochem J 1993;294:305–324.
107.
Englund PT: The structure and biosynthesis of glycosyl phosphatidylinositol protein anchors. Annu Rev Biochem 1993;62:121–138.
108.
Ferguson MAJ, Brimacombe JS, Brown JR, Crossman A, Dix A, Field RA, Guther ML, Milne KG, Sharma DK, Smith TK: The GPI biosynthetic pathway as a therapeutic target for African sleeping sickness. Biochim Biophys Acta 1999;1455:327–340.
109.
Naik RS, Branch OH, Woods AS, Vijaykumar M, Perkins DJ, Nahlen BL, Lal AA, Cotter RJ, Costello CE, Ockenhouse CF, Davidson EA, Gowda DC: Glycosylphosphatidylinositol anchors of Plasmodium falciparum: Molecular characterization and naturally elicited antibody response that may provide immunity to malaria pathogenesis. J Exp Med 2000;192:1563–1576.
110.
Karunaweera ND, Grau GE, Gamage P, Carter R, Mendis KN: Dynamics of fever and serum levels of TNF are closely associated during clinical paroxysms in Plasmodium vivax malaria. Proc Natl Acad Sci USA 1992;89:3200–3203.
111.
Bate CA, Taverne J, Playfair JHL: Malaria exoantigens induce T-independent antibody that blocks their ability to induce TNF. Immunology 1990;70:315–320.
112.
Ghigo D, Todde R, Ginsburg H, Costamagna C, Gautret P, Bussolino F, Ulliers D, Giribaldi G, Deharo E, Gabrielli G, et al: Erythrocyte stages of Plasmodium falciparum exhibit a high nitric oxide synthase (NOS) activity and release of NOS-inducing soluble factor. J Exp Med 1995;182:677–688.
113.
Desowitz RS, Elm J, Alpers MP: Plasmodium falciparum-specific immunoglobulin G (IgG), IgM, and IgE antibodies in paired maternal-cord serum from East Sepik Province, Papua New Guinea. Infect Immun 1993;61:988–993.
114.
Bouharoun-Tayoun H, Attanath P, Sabchareon A, Chongsuphajaisiddhi T, Druilhe P: Antibodies that protect humans against Plasmodium falciparum blood stages do not on their own inhibit parasite growth and invasion in vitro, but act in cooperation with monocytes. J Exp Med 1990;172:1633–1641.
115.
Bouharoun-Tayoun H, Druilhe P: Plasmodium falciparum malaria: Evidence for an isotype imbalance which may be responsible for delayed acquisition of protective immunity. Infect Immun 1992;60:1473–1481.
116.
Maeno Y, Steketee RW, Nagatake T: Immunoglobulin complex deposits in Plasmodium falciparum-infected placentas from Malawi and Papua New Guinea. Am J Trop Med Hyg 1993;49:574–580.
117.
Czermak BJ, Sarma V, Blell NM, Schmal H, Friedl HP, Ward PA: In vitro and in vivo dependency of chemokine generation on C5a and TNF-α. J Immunol 1996;162:2321.
118.
Ward PA: Role of complement, chemokines, and regulatory cytokines in acute lung injury. Ann NY Acad Sci 1996;796:104–112.
119.
Udomsangpetch R, Chivapat S, Viriyavejkul P, Riganti M, Wilairatana P, Pongponratin E, Looareesuwan S: Involvement of cytokines in the histopathology of cerebral malaria. Am J Trop Med Hyg 1997;57:501–506.
120.
Clark IA, Awburn MM, Whitten RO, Harper CG, Liomba NG, Molyneux EM, Taylor TE: Tissue distribution of migration inhibitory factor and inducible nitric oxide synthase in falciparum malaria and sepsis in African children. Malar J 2003;2:6.
121.
Pino P, Vouldoukis I, Dugas N, Hassani-Loppion G, Dugas B, Mazier D: Redox-dependent apoptosis in human endothelial cells after adhesion of Plasmodium falciparum-infected erythrocytes. Ann NY Acad Sci 2003;1010:582–586.
122.
Wang JM, Walter S, Mantovani A: Re-evaluation of the chemotactic activity of tumor necrosis factor for monocytes. Immunology 1990;71:364–367.
123.
Vassalli P: The pathophysiology of tumor necrosis factors (review). Annu Rev Immunol 1992;10:411–452.
124.
Verhoeven AJ, Bolscher BGJM, Roos D: The superoxide generating enzyme in phagocytes: Physiology, protein composition, and mechanism of activation; in Pelfrey C (ed): Membrane Lipid Oxidation. . Boston, CRC Press, 1991, pp 42–59.
125.
Mohan K, Dubey ML, Ganguly NK, Mahajan RC: Plasmodium falciparum: Role of activated blood monocytes in erythrocyte damage and red cell loss during malaria. Exp Parasitol 1995;80:54–63.
126.
Allison AC, Eugui EM: A radical interpretation of immunity to malaria parasites. Lancet 1982;i:1431–1433.
127.
Mohan K, Dubey ML, Ganguly NK, Mahajan RC: Plasmodium falciparum induced perturbations of the erythrocyte antioxidant system. Clin Chim Acta 1992;209:19–26.
128.
Mohan K, Ganguly NK, Dubey ML, Mahajan RC: Oxidative damage of erythrocytes infected with Plasmodium falciparum: An in vitro study. Ann Haemotol 1992;65:131–134.
129.
Othoro C, Lal AA, Nahlen B, Koech D, Orago AS, Udhayakumar V: A low interleukin-10 tumor necrosis factor-alpha ratio is associated with malaria anemia in children residing in a holoendemic malaria region in western Kenya. J Infect Dis 1999;179:279–282.
130.
May J, Lell B, Luty AJF, Meyer CG, Kremsner PG: Plasma interleukin-10:tumor necrosis factor (TNF)-alpha ratio is associated with TNF promoter variants and predicts malarial complications. J Infect Dis 2000;182:1570–1573.
131.
Kossodo S, Monso C, Juillard P, Velu T, Goldman M, Grau GE: Interleukin-10 modulates susceptibility in experimental cerebral malaria. Immunology 1997;91:536–540.
132.
Linke A, Kuhn R, Muller W, Honarvar N, Li C, Langhorne J: Plasmodium chabaudi chabaudi: Differential susceptibility of gene-targeted mice deficient in IL-10 to an erythrocytic-stage infection. Exp Parasitol1996;84:253–263.
133.
Li C, Corraliza I, Langhorne J: A defect in interleukin-10 leads to enhanced malarial disease in Plasmodium chabaudi chabaudi infection in mice. Infect Immun 1999;67:4435–4442.
134.
Wahl SM: Transforming growth factor beta: The good, the bad, and the ugly. J Exp Med 1994;180:1587–1590.
135.
Li C, Sanni LA, Omer F, Riley E, Langhorne J: Pathology of Plasmodium chabaudi chabaudi infection and mortality in interleukin-10-deficient mice are ameliorated by anti-tumor necrosis factor alpha and exacerbated by anti-transforming growth factor beta antibodies. Infect Immun 2003;71:4850–4856.
136.
Omer FM, Riley EM: Transforming growth factor beta production is inversely correlated with severity of murine malaria infection. J Exp Med 1998;188:39–48.
137.
Perkins DJ, Weinberg JB, Kremsner PG: Reduced interleukin-12 and transforming growth factor-β1 in severe childhood malaria: Relationship of cytokine balance with disease severity. J Infect Dis 2000;182:988–992.
138.
Lyke KE, Burges R, Cissoko Y, Sangare L, Dao M, Diarra I, Kone A, Harley R, Plowe CV, Duombo OK, Sztein MB: Serum levels of the proinflammatory cytokines interleukin-1 beta (IL-1β), IL-6, IL-8, IL-10, tumor necrosis factor alpha, and IL-12(p70) in Malian children with severe Plasmodium falciparum malaria and matched uncomplicated malaria or healthy controls. Infect Immun 2004;72:5630–5637.
139.
Esamai F, Ernerudh J, Janols H, Welin S, Ekerfelt C, Mining S, Forsberg P: Cerebral malaria in children: Serum and cerebrospinal fluid TNF-alpha and TGF-beta levels and their relationship to clinical outcome. J Trop Pediatr 2003;49:216–223.
140.
Bogdan C, Paik J, Vodokvotz Y, Nathan C: Contrasting mechanisms for suppression of macrophage cytokine release by transforming growth factor-β and interleukin-10. J Biol Chem 1992;267:23301–23308.
141.
Hermans IF, Ritchie DS, Yang J, Roberts JM, Ronchese F: CD8+ T cell-dependent elimination of dendritic cells in vivo limits the induction of antitumor immunity. J Immunol 2000;164:3095–3101.
142.
Kedl RM, Schaefer BC, Kappler JW, Marrack P: T cells down-modulate peptide-MHC complexes on APCs in vivo. Nat Immunol 2000;3:27–32.
143.
Hafalla JCR, Morrot A, Sano G, Milon G, Lafaille JJ, Zavala F: Early self-regulatory mechanisms control the magnitude of CD8+ T cell responses against liver stages of murine malaria. J Immunol 2003;171:964–970.
144.
Carvalho LH, Sano G, Hafalla JCR, Morrot A, Curotto de Lafaille MA, Zavala F: IL-4-secreting CD4+ T cells are crucial to the development of CD8+ T cell responses against malaria liver stages. Nat Med 2002;8:166–170.
145.
White NJ, Warell DA: Pathophysiological and prognostic significance of cerebrospinal fluid lactate in cerebral malaria. Lancet 1985;i:776–778.
146.
Krishna S, Waller DW, ter Kuile F, Kwiatkowski D, Crawly J, Craddock CF, Nosten F, Chapmann D, Brewster D, Holloway PA, White NJ: Lactic acidosis and hypoglycaemia in children with severe malaria: Pathophysiological and prognostic significance. Trans R Soc Trop Med Hyg 1994;88:67–73.
147.
Krishna S, Agbenyega T, Angus BJ, Bedu-Addo G, Ofori-Amanfo G, Henderson G, Szwandt IS, O’Brien R, Stacpoole PW: Pharmacokinetics and pharmacodynamics of dichloroacetate in children with lactic acidosis due to severe malaria. Q J Med 1995;88:341–349.
148.
Phillips RE, Looareesuwan S, Molyneux ME, Hatz C, Warrel DA: Hypoglycaemia and counterregulatory hormone responses in severe falciparum malaria-treatment with Sandostatin. Q J Med 1993;71:477–483.
149.
Curtis SE, Cain SM: Regional and systemic oxygen delivery/uptake relations and lactate flux in hyperdynamic, endotoxin-treated dogs. Am Rev Respir Dis 1992;145:348–354.
150.
Vallet B, Lund N, Curtis SE, Kelly D, Cain SM: Gut and muscle tissue PO2 in endotoxemic dogs during shock and resuscitation. J Appl Physiol1994;76:793–800.
151.
Hayano Y: Influence of induced hyperthermia on intestinal blood flow, translocation of endotoxin and other factors in mongrel dogs (in Japanese). Masui 1991;40:769–781.
152.
Hotchkiss RS, Karl IE: Re-evaluation of the role o f cellular hypoxia and bioenergetic failure in sepsis. JAMA 1992;267:1503–1510.
153.
Hotchkiss RS, Rust RS, Dence CS, Wasserman TH, Song SK, Hwang DR, Karl IE, Welch MJ: Evaluation of the role of cellular hypoxia in sepsis by the hypoxic marker [18F] fluoromisonidazole. Am J Physiol 1991;261:R965–R972.
154.
Warrel DA: Pathophysiology of severe falciparum malaria in man. Parasitology 1987;94:S53–S76.
155.
Elased K, Desouza J, Playfair JHL: Blood-stage malaria infection in diabetic mice. Clin Exp Immunol 1995;99:440–444.
156.
Elased K, Playfair JHL: Hypoglycemia and hyperinsulinemia in rodent models of severe malaria infection. Infect Immun 1994;62:5157–5160.
157.
Taylor TE, Molyneux ME, Wirima JJ, Fletcher KA, Morris K: Blood glucose levels in Malawian children before and during the administration of intravenous quinine for severe falciparum malaria. N Engl J Med 1988;319:1040–1047.
158.
Clark IA, Rockett KA: Nitric oxide and parasitic disease (review). Adv Parasitol 1996;37:1–56.
159.
Starnes HF, Warren RS, Jeevanandam M, Gabrilove JL, Larchian W: Tumor necrosis factor and the acute metabolic response to tissue injury in man. J Clin Invest 1988;82:1312–1325.
160.
Elased KM, Gumaa KA, de Souza JB, Rahmoune H, Playfair JH, Rademacher T: Reversal of type 2 diabetes in mice by products of malaria parasites. II. Role of inositol phosphoglycans (IPGs). Mol Genet Metab 2001;73:248–258.
161.
Brass EP, Vetter WH: Inhibition of gluca gon-stimulated glycogenolysis by S-nitroso-N-acetylpenicillamine. Pharmacol Toxicol1993;72:369–372
162.
Horton RA, Knowles RG, Titheradge MA: Endotoxin causes reciprocal changes in hepatic nitric oxide synthesis, gluconeogenesis, and flux through phosphoenolpyruvate carboxykinase. Biochem Biophys Res Commun 1994;204:659–665.
163.
Molina y Vedia L, McDonald B, Reep B, Brune B, Di Silvio M, Billiar T, Lapetina EG: Nitric oxide-induced S-nitrosylation of glyceraldehyde-3-phosphate dehydrogenase inhibits enzymatic activity and increases endogenous ADP-ribosylation. J Biol Chem1992;267:24929–24932.
164.
Benigni F, Atsumi T, Calandra T, Metz C, Echtenacher B, Peng T, Bucala R: The proinflammatory mediator macrophage migration inhibitory factor induces glucose catabolism in muscle. J Clin Invest 2000;106:1291–1300.
165.
Calandra T, Bucala R: Macrophage migratory inhibitory factor – A counter-regulator of glucocorticoid and critical mediator of septic shock. J Inflamm 1996;47:39–51.
166.
McDevitt M A, Xie J, Gordeuk V, Bucala R: The anemia of malaria infection: Role of inflammatory cytokines. Curr Hematol Rep 2004;3:97–106.
© 2005 S. Karger AG, Basel
2005
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.